294 related articles for article (PubMed ID: 9444984)
1. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted.
Amalfitano A; Hauser MA; Hu H; Serra D; Begy CR; Chamberlain JS
J Virol; 1998 Feb; 72(2):926-33. PubMed ID: 9444984
[TBL] [Abstract][Full Text] [Related]
2. Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity.
Osada T; Yang XY; Hartman ZC; Glass O; Hodges BL; Niedzwiecki D; Morse MA; Lyerly HK; Amalfitano A; Clay TM
Cancer Gene Ther; 2009 Sep; 16(9):673-82. PubMed ID: 19229288
[TBL] [Abstract][Full Text] [Related]
3. Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3.
Gorziglia MI; Lapcevich C; Roy S; Kang Q; Kadan M; Wu V; Pechan P; Kaleko M
J Virol; 1999 Jul; 73(7):6048-55. PubMed ID: 10364357
[TBL] [Abstract][Full Text] [Related]
4. Construction and characterization of E1-minus replication-defective adenovirus vectors that express E3 proteins from the E1 region.
Toth K; Kuppuswamy M; Doronin K; Doronina O; Lichtenstein D; Tollefson A; Wold W
Virology; 2002 Sep; 301(1):99-108. PubMed ID: 12359450
[TBL] [Abstract][Full Text] [Related]
5. An adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent deltaE1-E2-E3-E4 Ad5 vectors.
Catalucci D; Sporeno E; Cirillo A; Ciliberto G; Nicosia A; Colloca S
J Virol; 2005 May; 79(10):6400-9. PubMed ID: 15858023
[TBL] [Abstract][Full Text] [Related]
6. Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein.
Hodges BL; Serra D; Hu H; Begy CA; Chamberlain JS; Amalfitano A
J Gene Med; 2000; 2(4):250-9. PubMed ID: 10953916
[TBL] [Abstract][Full Text] [Related]
7. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement.
Ji L; Bouvet M; Price RE; Roth JA; Fang B
Gene Ther; 1999 Mar; 6(3):393-402. PubMed ID: 10435089
[TBL] [Abstract][Full Text] [Related]
8. Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors.
Everett RS; Hodges BL; Ding EY; Xu F; Serra D; Amalfitano A
Hum Gene Ther; 2003 Dec; 14(18):1715-26. PubMed ID: 14670123
[TBL] [Abstract][Full Text] [Related]
9. Protease-deleted adenovirus vectors and complementing cell lines: potential applications of single-round replication mutants for vaccination and gene therapy.
Oualikene W; Lamoureux L; Weber JM; Massie B
Hum Gene Ther; 2000 Jun; 11(9):1341-53. PubMed ID: 10890743
[TBL] [Abstract][Full Text] [Related]
10. Conditional repression of the E2 transcription unit in E1-E3-deleted adenovirus vectors is correlated with a strong reduction in viral DNA replication and late gene expression in vitro.
Rittner K; Schultz H; Pavirani A; Mehtali M
J Virol; 1997 Apr; 71(4):3307-11. PubMed ID: 9060700
[TBL] [Abstract][Full Text] [Related]
11. Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors.
Amalfitano A; Begy CR; Chamberlain JS
Proc Natl Acad Sci U S A; 1996 Apr; 93(8):3352-6. PubMed ID: 8622940
[TBL] [Abstract][Full Text] [Related]
12. Development of a recombinant adenovirus vector production system free of replication-competent adenovirus by utilizing a packaging size limit of the viral genome.
Suzuki T; Sasaki T; Yano K; Sakurai F; Kawabata K; Kondoh M; Hayakawa T; Yagi K; Mizuguchi H
Virus Res; 2011 Jun; 158(1-2):154-60. PubMed ID: 21470569
[TBL] [Abstract][Full Text] [Related]
13. Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII.
Andrews JL; Kadan MJ; Gorziglia MI; Kaleko M; Connelly S
Mol Ther; 2001 Mar; 3(3):329-36. PubMed ID: 11273775
[TBL] [Abstract][Full Text] [Related]
14. Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted.
Zhou H; O'Neal W; Morral N; Beaudet AL
J Virol; 1996 Oct; 70(10):7030-8. PubMed ID: 8794347
[TBL] [Abstract][Full Text] [Related]
15. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors.
Mizuguchi H; Kay MA
Hum Gene Ther; 1999 Aug; 10(12):2013-7. PubMed ID: 10466635
[TBL] [Abstract][Full Text] [Related]
16. A Cre-expressing cell line and an E1/E2a double-deleted virus for preparation of helper-dependent adenovirus vector.
Zhou H; Zhao T; Pastore L; Nageh M; Zheng W; Rao XM; Beaudet AL
Mol Ther; 2001 Apr; 3(4):613-22. PubMed ID: 11319924
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence.
Hehir KM; Armentano D; Cardoza LM; Choquette TL; Berthelette PB; White GA; Couture LA; Everton MB; Keegan J; Martin JM; Pratt DA; Smith MP; Smith AE; Wadsworth SC
J Virol; 1996 Dec; 70(12):8459-67. PubMed ID: 8970968
[TBL] [Abstract][Full Text] [Related]
18. Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy.
Amalfitano A; Chamberlain JS
Gene Ther; 1997 Mar; 4(3):258-63. PubMed ID: 9135740
[TBL] [Abstract][Full Text] [Related]
19. Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants.
Krougliak V; Graham FL
Hum Gene Ther; 1995 Dec; 6(12):1575-86. PubMed ID: 8664382
[TBL] [Abstract][Full Text] [Related]
20. Gutted adenoviral vector growth using E1/E2b/E3-deleted helper viruses.
Barjot C; Hartigan-O'Connor D; Salvatori G; Scott JM; Chamberlain JS
J Gene Med; 2002; 4(5):480-9. PubMed ID: 12221641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
